Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jiangsu Hengrui Medicine
Pharma
Hengrui, Takeda, and toripalimab's FDA nod—Fierce Pharma Asia
Merck KGaA licensed Hengrui's PARP drug. Novartis said an ex-staffer brought sensitive files to Takeda. The FDA cleared the first China-made PD-1.
Angus Liu
Nov 3, 2023 8:30am
Yuhan, Elevar, Hengrui and Astellas—Fierce Pharma Asia
Oct 20, 2023 8:35am
Hengrui, Elevar strike $600M marketing deal for liver cancer med
Oct 17, 2023 11:47am
Takeda, AstraZeneca, Astellas and more—Fierce Pharma Asia
May 19, 2023 9:25am
Astellas-Seagen, Eisai-Merck, BeiGene—Fierce Pharma Asia
Sep 9, 2022 10:09am
ESMO: Merck's Keytruda-Lenvima flop hands rivals a win
Sep 8, 2022 1:44pm